FLU JUST MET ITS GENETIC MATCH


Supemtek is included in latest 2022/23 Joint Committee on Vaccination and Immunisation (JCVI) recommendations for all eligible adult cohorts.1

Click here to download more information on Supemtek

Target influenza with Supemtek (Quadrivalent Influenza Vaccine, recombinant prepared in cell-culture), the first recombinant influenza vaccine in Europe. Supemtek is manufactured to offer an exact genetic match to the World Health Organization (WHO)-predicted viral strains.2,3

Supemtek Prescribing Information

Supemtek quadrivalent influenza vaccine is indicated for active immunisation for the prevention of influenza disease in adults.2

CLICK HERE TO ORDER 

Watch the video below to find out more about Supemtek's clinical data and safety profile.



THE UNDERESTIMATED THREAT OF INFLUENZA

A recent self-controlled case series study showed that adults aged 40 years and older (median age of 68 years), without a history of heart attack or stroke, were at an increased risk of severe cardiovascular complications in the 13 days following a confirmed influenza infection.*4

Patients were at a 10x increased risk of a first heart attack and 8x increased risk of a first stroke.*4

Each year in the UK, influenza vaccination could help to reduce the number of influenza cases and influenza-related premature deaths.5


INTRODUCING SUPEMTEK


RECOMBINANT TECHNOLOGY

Recombinant technology eliminates the possibility of adaptation or mutation by replicating only the haemagglutinin (HA) antigen direct from a genetic sequence. The resulting antigens are an exact genetic match to the target strain HA antigen.3,6


 

INCREASED HA CONTENT

Supemtek contains 3x more HA antigen (45 mcg versus
15 mcg) per strain, compared with cell- and egg-based standard-dose quadrivalent influenza vaccine.3


 

EFFICACY

Supemtek demonstrated 30% greater relative efficacy
(1% absolute efficacy) versus standard-dose egg-based quadrivalent inactivated influenza vaccine (QIVe), in preventing confirmed cases of influenza-like illness in adults aged 50+ years, with respective influenza attack rates of 2.2% and 3.2 %.†3


 

COMPARABLE SAFETY PROFILE

Supemtek demonstrated a comparable safety profile to standard-dose egg-based QIVe.3,7


 

SUPPORTED BY RANDOMISED CONTROLLED TRIALS

Randomised controlled trials support the efficacy and safety of Supemtek for active immunisation for the prevention of influenza disease in adults aged 18+ years.3,7


 

COMPARISON VERSUS STANDARD INFLUENZA VACCINES

Results from a European Centre for Disease Prevention and Control (ECDC) systematic literature review to assess the efficacy, effectiveness and safety of enhanced influenza vaccines (versus standard-dose or placebo) for the prevention of laboratory-confirmed influenza in adults aged 18+ years suggested that Supemtek may offer ”better protection than no vaccination, or standard influenza vaccines.”(QIVe)8


*As measured by age- and season-adjusted incidence ratios for myocardial infarction (n=1227) or stroke (n=762) in adults aged 40 years or older, in the 1-3 days following a laboratory-confirmed influenza infection. Adjusted IRs were 9.80 (95% CI 2.37–40.5) and 7.82 (95% CI 1.07–56.9) for myocardial infarction and stroke, respectively.4

As measured by relative vaccine efficacy (rVE) in adults aged 50+ years, randomised 1:1 to receive single dose of Supemtek (n=4303) or standard-dose egg-based QIVe (n=4,301) during the 2014/15 influenza season
(95% CI 10–47; P=0.006). Influenza attack rates were 2.2.% and 3.2% for Supemtek and standard-dose QIVe, respectively. The lower bound (LB) of the 95% confidence interval met the pre-specified, exploratory criterion for superior rVE LB >9%. Primary endpoint: rVE against reverse transcription polymerase chain reaction-confirmed, protocol-defined, influenza-like illness caused by any influenza strain starting 14 days or more after vaccination.3

CLICK HERE FOR VACCINATION LIVE WEBINARS

CI, confidence interval; ECDC, European Centre for Disease Prevention and Control; HA, haemagglutinin; JCVI, Joint Committee on Vaccination and Immunisation; LB, lower bound; QIVe, quadrivalent inactivated influenza vaccine; rVE, relative vaccine efficacy; WHO, World Health Organization.


REFERENCES:

  1. Joint Committee on Vaccination and Immunisation. Advice on influenza vaccines for 2022/23. https://app.box.com/s/t5ockz9bb6xw6t2mrrzb144njplimfo0/file/863135232161 [Accessed October 2021]
  2. Quadrivalent Influenza Vaccine (recombinant, prepared in cell culture) Summary of Product Characteristics. Sanofi Pasteur [September 2021].
  3. Dunkle LM, et al. N Engl J Med. 2017;376:2427–36.
  4. Warren-Gash C, et al. Eur Resp J. 2018;51:1701794.
  5. Franklin B and Hochlaf D. An economic analysis of flu vaccination. https://ilcuk.org.uk/wp-content/uploads/2018/07/An_economic_analysis_of_flu_vaccination_-_ILC-UK.pdf.
    [Accessed October 2021].
  6. Centers for Disease Control and Prevention. How influenza (flu) vaccines are made. https://www.cdc.gov/flu/prevent/how-fluvaccine-made.htm#recombinant [Accessed October 2021].
  7. Dunkle LM, et al.  J Infect Dis. 2017;216:1219–26.
  8. ECDC (2020) Systematic review of the efficacy, effectiveness, and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over. https://www.ecdc.europa.eu/sites/default/files/documents/seasonal-influenza-vaccines-systematic-review-efficacy.pdf [Accessed October 2021].


Date of preparation: November 2021 | MAT-GB-2003349(v3.0)

Reporting side effects
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on 0800 0902 314. Alternatively send via email to
UK-drugsafety@sanofi.com